← Press release

MagnaPharm and Kwizda Pharma enter into an exclusive partnership for the distribution and promotion of key Kwizda Pharma brands in Bulgaria, Hungary, Poland and Romania.

April 8th, 2020

MagnaPharm and Kwizda Pharma have entered into an Exclusive Distribution and Promotion Agreement of Kwizda’s brands in CEE markets of Bulgaria, Hungary, Poland and Romania. The Partnership is covering distribution and promotion of brands such as Bronchostop, Leaton, Sedogelat/Sedorelax and Ergotop. Flagship of the cooperation is Bronchostop brand. Bronchostop is a traditional herbal medicinal anti-cough product, available in forms of syrup, spray and pastilles. Bronchostop is the only natural pharmaceutical anti-cough product, which is approved in both cough indications, for productive and for dry cough. With such unique position Bronchostop is established as leading anti-cough product in its home market Austria and is very successfully marketed in many other markets globally, such as UK, Ireland, Spain, Netherlands, Hungary, Bulgaria, Croatia, Australia and many others. MagnaPharm is one of leading players in the cough & cold segment in CEE and offer an excellent platform to grow Bronchostop and the other Kwizda brands. Total anti-cough market in Bulgaria, Hungary, Poland and Romania is EUR 130 million annually.

“We are excited and proud to announce our partnership with Kwizda. For several years we are a leading OTC and cough & cold player in targeted CEE markets. Kwizda’s unique brands and its strong marketing expertise of the segments perfectly fits with our existing Cough and Cold portfolio structure and we believe we create a great base to further growth of existing sales of Kwizda portfolio in Hungary and Bulgaria and launch of Kwizda portfolio in Romania and Poland. The cooperation will help us to maintain and grow MagnaPharm’s leading presence in OTC and cough & cold segment in CEE. We look forward to working with Kwizda in achieving our milestones and setting a new standard within anti-cough products.”

Karol Michalak, CEO MagnaPharm